Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buy, Hold, Accumulate! $$$$TPIV$$$$
Yep.........I couldn't fit it all in one coffee can! .59 average
Yep!! 139,350 pieces of gold........just have to be patient here! Slow and Steady!
Exactly........this one might be priceless!
Agree.......my shares are buried in my backyard! I have a three time horizon.......I think something big will happen sooner if the ph 2 begin to mirror the ph 1 results in a much larger cohort! Just IMO!
When I do the math at $14/share I get light headed! LOL
It's just a nice round number! If their Ph 2 trials go anywhere near as well as Ph 1 that price will be a bargain!
I'm good with $1 billion!
I understand as I was in the same predicament myself 18 years ago! I pray that TPIV will save them as I was saved!
Perfect thanks! $$$$TPIV$$$$
Lasers.......do the wait until all patients are recruited before they begin the injections or do they perform the injection when the person qualified and is accepted as part of the cohort?
Yep mine are still buried!
Talk about manipulation! Jeez!
I really think this one will go exponential one day! That will be fun! All IMO!
I'm good if it gets to $10 in three years! It has been tough to watch the last few days......hang in there......better days are on the way! IMO
I just did the math for mine.....139,350 X $10 = 1,393,500! I'm callin in gone! LOL
Count me in! Go TPIV!
Are we up pre market? Anybody have L2?
Patience really is a virtue!
OK......so to confirm so I don't miss it it's 10AM central time
Oops yep Vegas Sure is in pacific time! Thx
Hell no!
I see its at 8AM.....since its in Vegas is that mountain time? So 9AM central?
Yes.....MollerMan......I keep him in a short leash! Just in case! LOL
Yes it is! 18 years out now!
That's the plan......a toast to our new found wealth and that we all were part of some amazing history! Getting that much closer to a cure of this never ending plague! I've had it and survived only because my older brother was an exact match for a bone marrow transplant on December 16, 1998!
Too funny! One day we will all have to meet in Vegas......I'm buying!
Email?
Is your middle name Nostradamus?
I've got my shares in a lock box buried in my back yard! Go TPIV!!
I know I won't have the where with all to hold this one to $100.......only way is if I fall asleep under a tree for ten years and wake up with almost 14 million bucks in my Schwab account! Sounds like a fairy tale huh? LOL
Check this out......our new theme song! ROFLMAO!
I'm sitting on 130,000 shares! $14 and "I call in gone!" LOL
I wish I could have been there too! All we need to do is be patient! It will be hard for me not to pull the trigger too soon! We may all need each other's support when that time comes........be it one year or three. I am long on TPIV!
This came to me in an email today.........more and more exposure!
From: "Financial Insights" <tpiv.investors@gmail.com>
Date: April 27, 2016 at 6:08:10 PM CDT
To: <daerga72@yahoo.com>
Subject: TPIV News 4-26-16
Industry news regarding TapImmune (TPIV). For continued updates call Financial Insights 866-359-7541
AstraZeneca Beefs Up Immuno-Oncology Pipeline with TapImmune Technology
Accesswire
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / AstraZeneca (AZN), a big pharma leader in immuno-oncology has placed its bets on a cancer vaccine technology from TapImmune (TPIV). Amongst a bevy of partnerships, collaborations, and M&A activity between big pharma and innovative biotechs focused on immunotherapies that treat cancer, TapImmune is getting much deserved attention from its bigger brethren looking to fill their pipelines with the most promising cancer cures.
A joint AstraZeneca-TapImmune Phase 2 ovarian cancer trial will start this quarter at the prestigious Sloan Kettering Institute, according to a press release issued a few days ago. The trial will test a combination therapy which includes TapImmune's TPIV 200, a T-cell cancer vaccine, with AstraZeneca's durvalumab an anti-PD-L1 antibody, in 40 women who have high-grade ovarian cancer and have not been responsive to platinum chemotherapy, currently the standard of care for advanced ovarian cancer.
Orphan Drug designation has already been granted by the FDA to TPIV 200 for ovarian cancer. The companies did not state when investors will hear top line data from this trial, however, the primary endpoint will look at efficacy rates 6 months post-treatment, so we may see results within the next three to four quarters.
With a current market cap of $45 million, Tapimmune is an extremely ripe acquisition target, even if acquired at multiple many times its current trading price. This is wholly justifiable given the company's hot immuno-oncology portfolio. TapImmune would be a very easy and very worthwhile acquisition for AstraZeneca, which is worth about $76 billion and is sitting on $6 billion in cash.
TapImmune is likely being sized up AstraZeneca's competitors, all vying for dominance the in the cancer immunotherapy space, including Roche (RHHBY), Merck (MRK), Johnson & Johnson (JNJ), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and others.
Pricing of recent deals shines a spotlight on how undervalued TapImmune is in the space. Merck recently signed a deal to pay $605 million for Israel-based cCAM Biotherapeutics. $95 million was paid upfront, with the balance of $510 million to come based on milestones, for a company whose lead candidate CM-24 is still in Phase 1. Merck is ready to spend after its drug, Keytruda, a PD-1 blocker got FDA approval for melanoma last year. Merck is also paying $375 million to buy OncoEthix for its Phase 1b drug OTX015, a BET inhibitor. $110 million was delivered up front with $265 million coming to OncoEthix upon completion of milestones. J&J just did a deal with Alligator Biosciences worth $700 million, for Alligator's Phase 1 CD40 targeting drug ADC-1013. Abbvie just did a $665 million deal with Argenx for ARGX-115 which is still in preclinicals.
$33 billion in annual sales by 2022 is projected by Morningstar for immuno-oncology drugs, which are expected to be very-high-margin products. This can hugely impact the profitability of big pharma, making acquisitions of technologies like TapImmune's all the more valuable. Further fueling the fire are the FDA's recent approvals of immuno-oncology drugs Opdivo and Keytruda.
TapImmune has much more to offer than TPIV 200 for ovarian cancer. TPIV 200 is also in a U.S. Department of Defense funded Phase 2 trial for triple negative breast cancer at the world renowned Mayo Clinic. TPIV 100 is headed into Phase 2 for HER2/neu breast cancer. The company's preclinical pipeline also holds promise for some very innovative new vaccines.
Big pharma tapping into TapImmune as an acquisition candidate is likely. Merck Research Laboratories'
Vice President and Therapeutic Area Head of Oncology Early Stage Development, Eric Rubin stated Merck is "scouring the world, looking for immunomodulatory agents." Based on recent M&A activity, Merck is not alone.
RAY DIRKS Research suggests that Readers/Investors place no more than 1% of the funds they devote to common stocks in any one issue. It's best to diversify.
About Ray Dirks
Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high -net worth investors both in the U.S. and internationally.
In 1973 Ray uncovered the biggest Ponzi scheme of the 20th century, the Equity Funding fraud. Over the years Ray has expanded his stock market research to include Healthcare Stocks and Special Situations. Ray has written two books, "The Great Wall Street Scandal" and "Heads You Win, Tails You Win", published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals, and he manages money for some individual investors.
Media Contact:
Jackie Rodriguez
646-430-5783
SOURCE: RAY DIRKS Research
Gotta Love That!
Sort of makes the hair on the back of my neck stand up and I get all tingly!
$$$$TPIV$$$$
I added 20,000 more yesterday! I'm here for the long haul! Figuring this will percolate just in time for my retirement date of 11/1/2019!
My 122,850 shares at .59 are looking sweet too! Can't wait for the news to propel this thing.....it's coming........patience now is key! GLTA!